Cape Investment Advisory’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$557K Buy
464
+39
+9% +$39.8K 0.15% 117
2026
Q1
$391K Buy
425
+154
+57% +$156K 0.13% 143
2025
Q4
$292K Buy
271
+238
+721% +$228K 0.09% 171
2025
Q3
$25.2K Sell
33
-153
-82% -$114K 0.02% 294
2025
Q2
$145K Buy
186
+16
+9% +$12.4K 0.05% 217
2025
Q1
$141K Sell
170
-22
-11% -$18.3K 0.06% 212
2024
Q4
$148K Buy
192
+28
+17% +$23.2K 0.06% 202
2024
Q3
$145K Sell
164
-5
-3% -$4.5K 0.06% 203
2024
Q2
$153K Sell
169
-12
-7% -$9.6K 0.07% 179
2024
Q1
$141K Sell
181
-35
-16% -$24.9K 0.07% 178
2023
Q4
$126K Sell
216
-15
-6% -$8.76K 0.06% 195
2023
Q3
$124K Sell
231
-20
-8% -$10.3K 0.07% 186
2023
Q2
$118K Sell
251
-25
-9% -$10.5K 0.07% 185
2023
Q1
$94.8K Buy
+276
New +$93.1K 0.06% 193

Other funds holding LLY

Cape Investment Advisory's LLY Position: Q2 2026 in Review

Cape Investment Advisory increased its Eli Lilly (LLY) stake by 9.2% in Q2 2026, buying an estimated $39.8K and bringing the position to 464 shares worth $557K. The position accounts for 0.15% of the portfolio, ranked #117.

Cape Investment Advisory first reported a position in LLY in Q1 2023 and has held it in 14 quarters since. 1,583 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Cape Investment Advisory held 464 shares of Eli Lilly worth $557K as of Q2 2026.
  • Cape Investment Advisory bought 39 Eli Lilly shares in Q2 2026, an estimated $39.8K.
  • Eli Lilly made up 0.15% of Cape Investment Advisory's portfolio in Q2 2026, its #117 holding.
  • Cape Investment Advisory first reported a position in Eli Lilly in Q1 2023 and has held it in 14 quarters since.
  • 1,583 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Cape Investment Advisory's 13F filing for Q2 2026, filed 23 Jul 2026.